Andrew Linden
All posts from Andrew Linden
Andrew Linden in Your News,

PTCT - is it a recovery?

PTCT announced that the National Institute for Health and Care Excellence (NICE) has recommended Translarna (ataluren) for ambulatory patients aged five years and older with nmDMD in connection with a Managed Access Agreement with NHS England.

From the beginning, Translarna is one of the key drugs in their portfolio and such news could be great for the company. Translarna is a drug for nonsense mutation Duchenne muscular dystrophy (nmDMD) treatment. There are less than 200,000 cases per year with this disease in the United States:

According to Medline Plus: "Duchenne muscular dystrophy is a form of muscular dystrophy. It worsens quickly. Other muscular dystrophies (including Becker's muscular dystrophy) get worse much more slowly."

Exploring the potential treatment, I found several options:

  • Albuterol--a drug used for people with asthma
  • Amino acids
  • Carnitine
  • Coenzyme Q10
  • Creatine
  • Fish oil
  • Green tea extracts
  • Vitamin E

To be honest, such treatment as fish oil, vitamin E or green tea extracts are looking to unreliable. Coenzyme Q10 is basically the vitamins, so I am not so sure that it could be the most efficient way of treatment. So, the overall list doesn't seem to good, so this is a real chance for Translarna to become a market leader. 

Then I just took a look at company's financials. They are not too promising:

Operating expenses are over than $200M, while the revenue is just $37M. We'll see if Translarna is good enough to reach $200-300M in sales, but it looks like the stock started its recovering.

Your thoughts?